Absci and Owkin announced a partnership to develop novel therapeutics using advanced AI technologies for disease treatment.
Quiver AI Summary
Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug creation, will work with Owkin's predictive AI technology to co-develop therapeutic candidates targeting areas like immuno-oncology and immunology. The collaboration aims to streamline the transition from research to clinical development by leveraging extensive biomedical datasets and AI-driven design. Both companies bring significant experience and partnerships in the biotech field, with Absci enhancing its drug creation capabilities alongside Owkin's expertise in AI-driven therapeutics and diagnostics. This partnership is part of Absci's strategy to expand its partnerships and drug candidate pipeline in 2024.
Potential Positives
- This partnership with Owkin enhances Absci's capabilities in drug discovery, potentially leading to the creation of first-in-class therapeutics.
- Absci's collaboration also expands its portfolio of partnerships, demonstrating its strategic growth and alignment with other industry leaders.
- The partnership aims to streamline the path from research to clinical development, which could accelerate time-to-market for new therapeutics.
- Absci's advanced AI and wet lab technologies significantly increase the efficiency of drug candidate development, showcasing its competitive advantage in the biotech sector.
Potential Negatives
- Partnerships with multiple companies, while highlighting collaboration, may suggest a lack of standalone achievements or capabilities within Absci itself.
- The forward-looking statements may raise concerns regarding the uncertainty and risk associated with the actual outcomes of their drug development and collaboration, potentially reflecting vulnerabilities in their strategy.
FAQ
What is the partnership between Absci and Owkin about?
The partnership aims to combine their AI platforms to rapidly discover and design novel therapeutics for patients.
How will Absci and Owkin's technologies collaborate?
Absci's AI de novo design will merge with Owkin's predictive AI for optimized target discovery and therapeutic candidate design.
What therapeutic areas will this collaboration focus on?
The collaboration will focus on immuno-oncology, immunology, and inflammation targeting novel therapeutic candidates.
What is Absci's approach to drug creation?
Absci utilizes a data-first generative AI drug creation platform to develop biologics more efficiently and effectively.
What previous partnerships has Absci formed?
Absci has partnered with industry leaders like AstraZeneca and Merck, enhancing its drug creation capabilities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ABSI Hedge Fund Activity
We have seen 60 institutional investors add shares of $ABSI stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC added 2,490,082 shares (+1919.3%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 846,826 shares (-100.0%) from their portfolio in Q3 2024
- ARK INVESTMENT MANAGEMENT LLC added 833,734 shares (+15.1%) to their portfolio in Q3 2024
- BOXER CAPITAL, LLC removed 700,000 shares (-100.0%) from their portfolio in Q3 2024
- ADAR1 CAPITAL MANAGEMENT, LLC removed 692,779 shares (-40.8%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 661,273 shares (+15.4%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP added 615,725 shares (+41.7%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) --
Absci Corporation
(NASDAQ: ABSI), a data-first generative AI drug creation company, and
Owkin
, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.
“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI
de novo
design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”
Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its
de novo
antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.
“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”
This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics.
About Absci
Absci
is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our
Integrated Drug Creation
™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit
www.absci.com
and follow us on LinkedIn (
@absci
), X (Twitter) (
@Abscibio
), and
YouTube
.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment. We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded
MOSAIC
, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding the capabilities of our Integrated Drug Creation platform, our technology development efforts and the application of those efforts, the potential benefits of our partnership with Owkin, the plans and success of our current and future partnerships and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies, the anticipated value to us under our partnerships, and our internal therapeutic asset programs, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Absci Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Absci Media Contact
press@absci.com
Owkin Media Contact
Stephanie Libous
Director of Communications and PR
stephanie.libous@owkin.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
